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Abstract
There is growing concern about lack of scientific rigor and transparent reporting acrossmany preclinical fields of biological research. Poor
experimental design and lack of transparent reporting can result in conscious or unconscious experimental bias, producing results that are
not replicable. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)
public–private partnership with the U.S. Food and Drug Administration sponsored a consensus meeting of the Preclinical Pain Research
Consortium for InvestigatingSafety andEfficacy (PPRECISE)WorkingGroup. International participants fromuniversities, fundingagencies,
government agencies, industry, and a patient advocacy organization attended. Reduction of publication bias, increasing the ability of
others to faithfully repeat experimental methods, and increased transparency of data reporting were specifically discussed. Parameters
deemed essential to increase confidence in the published literature were clear, specific reporting of an a priori hypothesis and definition of
primary outcomemeasure. Power calculations andwhethermeasurement ofminimalmeaningful effect size to determine these should be
a core component of the preclinical research effort provoked considerable discussion, with many but not all agreeing. Greater
transparency of reporting should be driven by scientists, journal editors, reviewers, and grant funders. The conduct of high-quality science
that is fully reported should not preclude novelty and innovation in preclinical pain research, and indeed, any efforts that curtail such
innovation would bemisguided.We believe that to achieve the goal of finding effective new treatments for patients with pain, the pain field
needs to deal with these challenging issues.
Keywords: Transparent reporting, Consensus, Bias, Internal validity
1. Introduction
The scientific community is highly regulated and represents
a complex interplay of relationships between public and private
enterprises. Scientific discoveries relating to the basic biology of
pain are primarily disseminated through publication in peer-
reviewed journals. These studies inform the field, allowing the
generation of hypotheses that may yield novel pain therapeutics.
Despite great advances in the treatment of pain, there is a concern
that discovery of novel, efficacious therapeutics for pain has
slowed. Clinical trial failures raise many questions, including the
relevance of preclinical hypotheses and the accuracy of animal
models to predict the biology of the human condition. However,
because clinical trials are only performed after successful
replication at the preclinical level, their failure does not reflect
a lack of replicability of the original results, but more likely the
complexity of human clinical trials. Indeed, there are many
reasons why a compound may fail in clinical settings, such as
inability to use effective doses, failure to engage the target at the
correct time, unsuitable pharmacokinetics, wrong patient group,
large placebo response, insensitive outcome measures, and
patient drop out.
Aswell as the above issues, there is growing concern about the
lack of scientific rigor and transparent reporting8,10 across many
preclinical fields of biological research. Poor experimental design
and lack of transparency can result in conscious or unconscious
experimental bias19 that may result in findings that are not
replicable. Concerns have also been raised that similar problems
may exist in preclinical pain research.14,15 Experimental bias
(something that can be mitigated) differs from scientific fraud
(something that is virtually impossible to prevent if an individual is
determined) in that scientific fraud is the creation of data that were
either never generated at all or that were generated by methods
other than those described. Experimental bias is unintentional
and often a result of poor internal validity, which ultimately
prevents the scientist from correctly attributing an observed effect
to a particular treatment or intervention. Internal validity is
therefore extremely important both to scientists who are looking
to generate hypotheses based on reliable data and to scientists
seeking to test hypotheses reported in the literature.
Improved uniform reporting standards, and adoption of
experimental protocols that emphasize control of experimental
bias, are likely to improve understanding and confidence in pain
biology. Transparent reporting requires that authors fully describe
“what was actually done” and does not per se dictate the
experimental approach. Improving standards of reporting will
increase the number of articles that can be used for meta-
analyses. To address the issues discussed, the Preclinical Pain
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Research Consortium for Investigating Safety and Efficacy (PPRE-
CISE) Working Group was convened with the goal of identifying
important information that should be included in experimental
publications. Themany factors that influence the outcome of clinical
trials have been reviewed5 and will not be addressed here. Although
this commentary will focus on transparency of reporting and
improving experimental design primarily in behavioral experimenta-
tion, the general concepts to reduce bias should apply across all
scientific experimentation in preclinical pain studies.
2. Method
The Analgesic, Anesthetic, and Addiction Clinical Trial Translations,
Innovations, Opportunities, and Networks (ACTTION) public–
private partnership with the U.S. Food and Drug Administration
sponsored a consensusmeeting of the PPRECISEWorking Group
that took place on the 11th and 12th of July 2013. The entire group
included international participants from universities, government
agencies, industry, and a patient advocacy organization (ie, the
authors) and all attendees were present during all sessions on both
days. There were no “breakout” groups. Forty participants were
selected from the academic and pharmaceutical/biotechnology
fields on the basis of their research, clinical, or administrative
expertise relevant to the fundamental understanding of neurobio-
logicalmechanisms of pain and experimental design and preclinical
evaluation of treatments for chronic pain. The organizing committee
was Dr A. I. Basbaum, Dr F. Porreca, Dr A. S.C. Rice, and Dr C. J.
Woolf, with Dr R. H. Dworkin and Dr D. C. Turk representing
ACTTIONon an ex officio basis. The committee above chose all the
other participants/coauthors, based on their contribution to pain
research either as basic scientist, clinical scientist, or industry
scientist, or involved in publication or regulation of pain research
with an additional emphasis on including representative junior
investigators. The meeting was designed to reflect a broad
representation of relevant disciplines and perspectives, while
limiting the number of attendees to promote productive and
efficient discussion. Before the meeting, all attendees received 12
publications from the literature relating to reporting standards in
animal studies of pain (Rice et al.14,15 and Currie et al.4), stroke
(Macleod et al.10 and Sena et al.16), and articles more broadly
addressing reporting standards and experimental design across
biological research (Kilkenny et al.,8 van der Worp et al.,19 and
Landis et al.9). To facilitate discussion, meeting presentations were
organized into 3 main sessions: (1) design and reporting of
preclinical pain research (from the perspectives of academic and
industrial scientists, funders, and regulatory bodies); (2) reporting of
preclinical pain research (from an Editor’s perspective); and (3)
“good laboratory practice” domains: designing, conducting, and
reporting preclinical studies of pain—challenges and opportunities
(covering aspects of internal and external validities). The format
allowed for questions from the floor during the presentations and
further time was allocated at the end of each session for further
questions from the floor to the speakers as a panel.
The following is based on the background presentations and
extensive discussions and debates at the consensus meeting. A
draft manuscript was circulated to all authors and after iterative
revisions, a consensus was achieved; all authors approved the
final version of this article.
3. Results
During the meeting, attention was focused on 3 specific areas that
would have greatest impact on the ability to judge the validity of
conclusions made in published work studying pain and analgesia:
reduction of publication bias, increased ability to replicate the
findings of others, and increased transparency of reporting of data.
Preclinical research that reaches the level sufficient for publication
(ie, is not merely a “pilot” experiment) can be believed of as existing
in 2 distinct modes (Fig. 1): (1) exploratory or “hypothesis-
generating” research that aims to generate theories pertaining to
the pathophysiology of disease and (2) confirmatory or “hypoth-
esis-testing” research that aims to demonstrate reproducible
treatment effects in relevant animal models. Absolute conformity in
experimental design and execution of exploratory investigations
across laboratories and geographical boundaries is extremely
difficult to achieve, and spending time to reorganize one’s
environment to become optimized for full replication of other’s
work is probably not the best use of limited resources.Most believe
that scientists designing and reporting exploratory and confirma-
tory studies should use similar (if not the same) standards of rigor
and lack of bias, and this can be achieved by attending to some
simple and yet critical standards. Acknowledging that a study was
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
a Department of Neurobiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, b Department of Anatomy, University of California San Francisco, San
Francisco, CA, USA, c Department of Psychology and Alan Edwards Centre for Research on Pain, McGill University, Montreal, Canada, d Department of Pharmacology, College of
Medicine,University ofArizona, Tucson,AZ,USA, e PainResearch,Department of Surgery andCancer, Imperial College, London,UnitedKingdom, f Centre forClinical BrainSciences,
University of Edinburgh, Edinburgh, United Kingdom, Departments of g Anesthesiology, h Neurology, and, i Psychiatry, University of Rochester, Rochester, NY, USA, j Department of
Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA, k Department of Biostatistics, Harvard University, Boston, MA, USA, l Department of Anesthesiology,
University of Rochester, Rochester, NY, USA, m Clinical and Rehabilitative Medicine Research Program, United States Army Medical Research andMateriel Command, Fort Detrick,
MD, USA, n Department of Physiology and Pathophysiology, Friedrich-Alexander Universita¨t, Erlangen-Nu¨rnberg, Germany, o Institute of Medical Sciences, University of Aberdeen,
Aberdeen, United Kingdom, p Eli Lilly & Co., Indianapolis, IN, USA, q Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA, r Neuroscience Discovery
Research, Eli Lilly & Co., Indianapolis, IN, USA, s Policy Department,Wellcome Trust, London, United Kingdom,Departments of t Medicine and, u Oral Surgery, University of California
San Francisco, San Francisco, CA, USA, v National Centre for Replacement, Refinement & Reduction of Animals in Research, London, United Kingdom, w Kent, United Kingdom,
x Department of Biostatistics and Computational Biology and Department of Neurology, University of Rochester, Rochester, NY, USA, y Neurorestoration group, King’s College,
London, United Kingdom, z School of Behavioral and Brain Sciences, University of Texas at Dallas, TX, USA, aa Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA,
USA, bb Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, CA, USA, cc Department of Neurobiology, University of
Pittsburgh, Pittsburgh, PA, USA, dd Office of Career and Professional Development, University of California San Francisco, San Francisco, CA, USA, ee Faculty of Dentistry & Alan
Edwards Centre for Research on Pain, McGill University, Montreal, Canada, ff Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, gg Department
of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA, hh Discovery Research, Purdue Pharma, Cranbury, NJ, USA
*Corresponding author. Address: Kirby Neurobiology Center, Boston Children’s Hospital, Harvard Medical School, 3 Blackfan Circle, Boston, MA 02115, USA.
Tel.: 11 617 678 7494; fax: 11 617 919 2771. E-mail address: Nick.andrews@childrens.harvard.edu (N. A. Andrews).
PAIN 157 (2016) 901–909
© 2015 International Association for the Study of Pain. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.1097/j.pain.0000000000000458
902 N.A. Andrews et al.·157 (2016) 901–909 PAIN®
Figure 1. Comparison of different categories of experimental research, illustration of possible bias, and how this may be minimized with best practice to achieve a reliable
outcome.Nonrandomized clinical observations, which are typically case reports, are effectively phenotypic observations often of individuals. As such, the recommended
statistical approach is descriptive (summarizing the datawithoutmaking further interpretations) rather than inferential (meaning, formal hypothesis testing or estimation). Such
studies aremost useful for hypothesis generation because inferences are not beingmade and sobias is not an issue. For exploratory animal research, the hypothesis being
testedcanbe representedas “Is amechanism (A) associatedwith thediseaseprocess (eg,neuropathicpain) (B) or is it anepiphenomenon (A’)?”. Type1errorsoccurwhen the
null hypothesis is incorrectly rejected; that is, the result is a “false positive” (shown by an enhanced size of A within B in the lower half of the figure). False positives commonly
occurbecauseof experimental biasandarearguably ofmost concern in exploratory researchas it is farmore likely that a falsepositivewouldbepublished thana falsenegative
because of publication bias favoring the publication of “positive” findings supporting exciting new hypotheses. We propose that careful attention to internal validity (section 4)
can help reduce false positives and increase the rigor bywhich hypotheses are tested. Clear description of inclusion/exclusion criteria, use of appropriate statistical tests after
initial tests for normality, and controlling for multiplicity of statistical testing are all recommended to reduce biasing the importance of a finding. *It is possible to determine the
appropriate sample size using power calculations because an effect size can be estimated from the historical data generated using standard endpoints of pain assessment in
animals. **It might not be possible to determine the sample size using power calculationswhen both themechanism and the endpoint are novel; however, onemight want to
include a known analgesic or modulator of a known mechanism in the experimental design to better define assay sensitivity. Confirmatory (preclinical) research often
compares inapproachwithclinical trials anddealswith thequestionof, for example,whethercompound (A) is different fromvehicle (B) inmuch thesameway thatclinical trials
compare a test substancewith placebo. This type of experiment tests existing hypotheses (eg,whether antagonismof target A results in antihyperalgesia in a particularmodel
of neuropathic pain). We recommend that the use of power calculations to determine the appropriate sample size can and should be performed because themodel and the
endpointare typically validated,andeffect sizesof standardanalgesics in themodel and test areknown.Dose responses (rather thansingle-dosestudies) shouldbeperformed
when possible and should be analysed by the appropriate statistics after tests for normality and with post hoc analysis strategies controlled for multiplicity. It is also
recommended to include a comparator such as a positive control whenever possible to demonstrate assay sensitivity that should be expected from a known response.
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performed with such a set of standards would allow improved
ability to interpret the results of studies, a faster and more efficient
compilation of the results obtained in the pain field for meta-
analyses, and also hopefully reduce the impact of publication bias.
3.1. Problem of publication bias
Publication bias is present when research is published that does
not represent the total body of research conducted. In part,
publication bias results from the pressure to publish positive
studies in high-impact journals. Publication bias has been studied
extensively and to some extent mitigated in the clinical literature
(eg, by the requirement to register all trials in clinicaltrials.gov),
although the reporting of results of those trials is still not
guaranteed. Publication bias is less well studied in the basic
science/preclinical literature. In an analysis of several preclinical
studies in different fields, including stroke, Parkinson disease,
multiple sclerosis, and amyotrophic lateral sclerosis, it was
concluded that there was publication bias in many of these
areas.19 Among the contributors to this bias was failure to publish
“nonpositive” data. Nonpositive data can be divided into
“negative data” (a statistically significant effect in the direction
opposite from that hypothesized or from that already published)
and what we have termed “neutral data.” In our use of the term
neutral data, we include data that clearly show no statistically
significant effect over a narrow or wide confidence interval.
However, neutral data may also be described as “inconclusive
data” assuming that the confidence interval for the treatment
effect contains values that might be considered to be relevant.1
Failure to publish nonpositive data presents ethical concerns as
the same experiments may be repeated unnecessarily in other
laboratories. The lack of balance also leads to overtly optimistic
claims or the generation of inaccurate hypotheses.16 Conversely,
publication of negative or neutral findings based on poor
experimental methodology could deter others attempting repli-
cation, leaving the field with a false-negative result; thus, there is
a critical need for transparency in reporting all experimental
details so that the quality of research might be assessed.
3.1.1. Reducing publication bias
Ideally, the decision to publish an article should be primarily based
on the overall importance of the hypothesis being tested and the
rigor of experimental design, conduct, analysis, and reporting and
less on the “positivity,” “neutrality,” or “negativity” of results—all 3
types of findings are important for the field to know, provided the
studies are of high quality. However, in the hierarchy of “desirability
to publish,” there is noquestion that exciting, positive data are often
prioritized for publication over “negative” data largely irrespective of
the quality of experimental design and conduct; “neutral” data are
very low down the list, and it is difficult at present to see the culture
changing. With the exception of a few (eg, PLoS One), journals
rarely publish negative and neutral findings. Specifically to reduce
publication bias, what is needed is the publication of negative/
neutral data in opposition to previously published positive data (if
they exist). In essence, this greatly expands the “peer-review”
process. One possibility is that journals could make a section
available for letters or short communications where negative and
neutral data can be reported (with simple statements demonstrat-
ing attention to the internal validity of these studies, ie, random-
ization, blinding, sample sizes, concealed allocation, adequate
sample size). To be more palatable to the journals, these reports
could be considered outside the scope of impact factor calculation
while still being eligible for citation and future reviews. The value of
such publications would become clear in reviews where “positive”
findings could be set against available peer-reviewed “nonpositive”
data, giving the reader the opportunity to judge the validity of
a particular hypothesis or study. In addition, it should be noted that
funding agencies, at least in the United States, receive updates on
the progress of projects and could simply request that a brief
summary of experiments that did not produce positive results be
included; such data could be posted in a database accessible to
others. One specific database already exists for biomedical
research awards and contracts provided by the Department of
Defense (DoD). The DoD requires Principal Investigators to submit
thorough reports containing detailed experimental methods, data,
and explanations of any deviations from the original statement of
work. Reports are scientifically reviewed andPrincipal Investigators
are provided feedback if required. These reports are publicly
available at the Defense Technical Information Center (www.dtic.
mil). At the repository called “Figshare” (www.figshare.com), it is
already possible to post data in the form of articles, figures,
spreadsheets, and other formats that are shared publicly. Although
postings within Figshare are not refereed, these data could prove
useful to some investigators. These figures should be accompa-
nied by a brief discussion written by the scientist accompanying
any nonsignificant data, explaining possible reasons for lack of
significance (eg, incorrect hypothesis, methodology not optimized,
study underpowered). At present, all publicly available research on
Figshare gets allocated a DataCite DOI so that the research can be
cited. However, we also recognize that citing articles and results
that have not undergone peer review raise additional concerns,
and believe that the presentation of findings from these sources
should be accompanied by appropriate qualifications. It was
therefore recognized that journals and funders have an important
role to play in controlling publication bias.
3.2. Problem of repeating the work of others
A major requirement of scientific experimentation is the ability to
repeat the findings of others; in this way, observations move
closer to fact. Repeating experiments takes time and involves use
of resources that could be directed towards discovering new
findings. Nevertheless, if a scientist builds replication into any
study, then confidence in the findings should increase. Although
important throughout science, the need for replication is critical
before embarking on a drug discovery program. Failure to
replicate certainly raises a worry as to the robustness of the
reported findings but does not necessarily mean that the original
publication was incorrect as there may be environmental
variations and procedural factors beyond the control of the
different institutions that limit the ability to exactly recreate
experimental conditions that were described in the publication
being followed. Transparent reporting of experimental proce-
dures is therefore essential to enable others to repeat the
experimental procedures as faithfully as possible. Transparent
reporting will also facilitate the interpretation of study results and
meta-analyses that aggregate across studies bymaking sure that
low-quality studies can be accurately identified and excluded.
Transparent reporting has been shown to be a serious problem
with certain key components of internal validity—randomization,
blinding, and power calculations—only being reported in
a minority of publications sampled.7,15
3.2.1. Making replication easier and more attractive
Recent publications from Bayer3 and Amgen13 reported that the
percentage of published findings in high profile journals that could
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not be replicated internally was very high, at least in preclinical
cancer drug development, and these publications provoked
much discussion. Although the authors did not report their
experimental procedures or data regarding which studies were
not replicated, these 2 reports did bring to the surface the
worryingly high number of targets that are evaluated by scientists
in industry but dropped because of an inability to repeat
published findings. We should strive to improve reporting
standards to reduce this attrition.
One recent attempt was reported8 to improve the ability across
laboratories to repeat experiments. The publication consisted of
a very detailed set of reporting guidelines called ARRIVE (Animal
Research: Reporting In Vivo Experiments) that listed 20 separate
items in a checklist to consider when writing a scientific article
(see https://www.nc3rs.org.uk/arrive-guidelines). At the time of
publication, the authors noted that although there were reporting
guidelines for clinical trials (CONSORT) and metabolomics and
gene expression studies, guidelines for reporting in vivo experi-
ments were lacking. Many journals now recommend using the
ARRIVE guidelineswhen reporting in vivo experiments, but, as yet
there is little association between endorsement of preclinical
guidelines by journals and their general adoption by the
community, even at the most impactful publications.2 Whether
the adoption of rigorous reporting guidelines such as ARRIVE has
a positive impact on experimental reporting standards and
preclinical reproducibility remains to be determined.
In terms of making replication more attractive, scientists could
be encouraged to repeat work through the use of multicenter
consortia; although the overall cost would be higher, the cost to
each individual group would be the same. As the consortium
would be working together, methodological details would be
shared and experiments faithfully performed in different labora-
tories according to standardized protocols. An example of this
approach is already evident in Europe through the Innovative
Medicines Initiative that funds Europain (http://www.imi.europa.
eu/content/europain), consortia of academic and industrial
scientists studying the effect of chronic pain on different biological
domains. This consortium approachwould seem to be a relatively
efficient way to evaluate the robustness of a particular finding.
Although this approach is clearly not possible for every new
finding, collaboration is an option open to scientists in general.
Industry often has the technical capacity to replicate, and ideally,
this resource should be tapped for precompetitive studies in
public–private partnerships.
3.3. Problem of data presentation (increasing transparency)
The most common way to present data from a continuous
outcome variable is to show a figure, such as a bar chart or line
graph, that illustrates themean6SD (ormore commonly SEM). A
P value is often calculated indicating the probability of observing
group differences at least as extreme as that observed if there
was no true group difference (eg, no effect of the intervention).
However, “P” values are poor summaries of evidence, as they do
not convey information regarding the magnitude of the effect, the
variability of the responses, and the biological relevance of the
findings. Transparent presentation of experimental data would
enable others to better evaluate the significance of the findings.
3.3.1. Clearer methods of data presentation
A better way to show data than simply showing the mean 6 SEM
may be to report all individual points in each experimental group.
This approach gives the reader the best appreciation of the
variability and distribution of the data. An excellent option for
presentation of results is to provide confidence interval estimates of
the parameters of interest (eg, difference in means between
groups). Thewidth of the confidence interval indicates the precision
associatedwith the estimate. A verywide interval could indicate that
more data are required before a useful conclusion can be drawn as
to the magnitude of the effect, if any. In the case of a difference in
means betweengroups, the confidence interval would fail to include
the value of zero if, and only if, the group difference is statistically
significant. This duality between confidence interval estimation and
hypothesis testing is useful for interpretation of the results.
4. Reducing experimental bias andmisinterpretation
of results by enhancing internal validity
There is a concern that the biological significance of many
findings in the preclinical arena is exaggerated and a typical
concluding sentence similar to “the findings of this study
demonstrate that X may be a novel treatment for pain or a target
for novel analgesics,” although absolutely not unique to pain
research findings, is often not adequately supported by the data
presented but may help to get the article published in a high
impact journal. To counter this, reducing experimental bias by
enhancing internal validity should lead to more robust, re-
producible observations and should therefore be routinely
considered when designing preclinical experiments (Table 1).
As alluded to in the Introduction, a number of aspects of study
design that influence internal validity, if not given sufficient
attention, may, alone or in combination, lead to bias and incorrect
interpretation of results.12,15 In some cases, it is possible that the
effects of blinding and randomization may be small, but this does
not mean that they should not be used wherever possible to
reduce bias because there are many instances where these
factors can influence effect sizes. A recent systematic review of
publications reporting findings from the use of bone cancer pain
models in animals underscored the importance of internal
validity.4 The authors identified 831 unique records from three
electronic databases (PubMed, ISI Web of Science, and Ovid
Embase in July 2011) of which 150 satisfied their eligibility criteria.
In common with other meta-analyses, only a third of the articles
analyzed (from a total of 150) reported the use of blinding, 11%
reported randomization, and none of the publications reported
sample size calculations. Overall, the authors concluded that
those studies reporting measures to reduce bias found smaller
differences in behavioral outcomes between tumor-bearing and
control animals. The findings in the study just described are very
similar to those reported in Reference 14 in a small sample study
of preclinical nerve injury studies. A number of key considerations
that should be used to reduce bias are listed in Table 1 and
discussed below.
4.1. Sample size
Sample size refers to the number of experimental units (eg,
individual animal, cage of animals). Inadequate sample size is
a primary reason for incorrect conclusions. A sample size that is too
small runs the risk of failing to detect important effects; however,
a sample size that is too large puts more animals at risk than
necessary and is wasteful of resources. Sample size, therefore, is
not only relevant to the possibility of incorrect interpretation of the
findings but also raises ethical issues. One of the goals of the in vivo
scientist is to use the minimum number of animals consistent with
the scientific objective (the 3Rs principle of reduction), and this
number can be determined using power calculations. Using too
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many or too few animals would be inconsistent with the 3Rs
principle. This concern is also addressed by institutional review
boards when reviewing clinical trials—the minimum number of
humans should be exposed to the risk of the intervention to
adequately test the hypothesis. In a recent study,6 2095 citations
were examined that reported 26 different sets of guidelines for the
conduct of preclinical efficacy studies across several fields of
science. These 26 sets of guidelines contained 55 distinct
recommendations. The authors found that 23 of the 26 sets of
guidelines stated the need for power calculations.However, despite
recognition of the importance of power calculations, the reporting of
their use is routinely less than 10% in articles sampled.14,16
In the pain field, across a broad range of assays, the median
sample size seems to be approximately n 5 9 rats or mice per
group.11 However, because of the lack of reporting of power
calculations to determine group sample sizes, it is not clear
whether the sample sizes are due to convention or to formal
consideration of the power of the study. There is no magic
number for group sample size because different study designs,
including different outcome variables, yield different sample size
requirements. The number of animals in an experiment, like the
number of humans in a clinical trial, should be determined by
a process: specification of a scientific hypothesis, translation into
a statistical hypothesis, and specification of other design
elements such as the primary outcome variable, the primary
statistical test to be used, the significance level for the test, the
desired power, the variance of the outcome variable (for
a continuous outcome variable), and the group difference to be
detected (effect size). Specification of the latter 2 quantities (ie,
variance and effect size) can present challenges in preclinical
studies, particularly if novel phenomena are being investigated.
Pilot studies can be helpful in this regard before undertaking
a confirmatory experiment. Indeed, it is stated in the U.S. Guide
for the Care and Use of Laboratory Animals that “If little is known
about a specific procedure, limited pilot studies, designed to
assess both the procedure’s effects on the animals and the skills
of the research team and conducted under IACUC oversight, are
appropriate” (p. 26). In addition, scientists should consider
determining the size of an effect (group difference) that they
would need to observe to be convinced that the treatment or
intervention is worth investigating further.
Transparency in how a sample size was derived can also help
provide context for interpretation in the face of multiple significance
tests. Suppose that, during the course of an experiment, a test was
conducted on a small number of mice and the result was not
significant at a significance level of 5%. The investigator then added
mice to the experiment and repeated the test at the 5%significance
level, this time obtaining a significant result. The result of the final
test is then reported in the literature. The false-positive error rate for
this experiment, however, is greater than 5% given that multiple
testswere conducted. Theuseof amore stringent significance level
to account for multiple testing and the sequential nature of the
experiment would be indicated in this case.
A formal sample size calculation can be recommended for
confirmatory hypothesis testing studies. The role of such
a calculation in exploratory hypothesis-generating studies is less
clear. We recommend that authors of the reports of preclinical
research provide transparency as to whether the study is
exploratory or confirmatory, and if a power calculation was not
performed, to explicitly state this in theMethods section. The total
number of significance tests performed should also be reported
to provide multiplicity context (section 4.6).
This particular topic produced by far the most discussion with
opposing views being extensively discussed on the merits of the
need for such formal determination of sample size. Overall, most
meeting participants believed that preclinical studies that tested
a statistical hypothesis should rely on formal determination of
sample size rather than on convention. Without a sufficient
number of animals per experimental group, statistical power is
reduced and the interpretability of the results is compromised. As
standards of reporting increase, meta-analyses may help de-
termine adequate group sizes for common endpoints used to
measure pain in animals.
4.2. Concealed allocation
Concealed allocation refers to the practice of concealing the
group or treatment assignment (ie, the allocation) of each
experimental subject from the investigator (eg, the surgeon) until
the moment of assignment. By shielding the investigator from
knowing the group to which the next animal will be allocated,
researchers are prevented from influencing which subjects are
Table 1
Recommendations to reduce bias and aid transparency: bias
can be reduced by carefully considering aspects of internal
validity in the experimental design before initiation (upper
panel).
Internal validity
Randomization What randomization strategy was used to
prevent selection bias (eg, randomisation
across cages, genotypes, time of day)?
Concealed allocation and
blinding
Was the researcher administering treatments
or injuries or assessing the results blinded to
the allocation of the treatments and
experimental conditions?
How was the researcher blinded for analysis of
results?
Sample size Has a power or precision calculation been
performed to establish appropriate group
sizes? What is the scientific justification for the
number of animals?
Eligibility criteria Were animals removed from the study?
What were the predetermined eligibility
criteria?
Statistical methods What statistical methods were used?
How were the assumptions associated with the
statistical methods evaluated?
Were multiple statistical tests performed (eg,
many group comparisons or many outcomes)?
If so, how was the issue of multiplicity
addressed to control the probability of a type I
error?
Results Clearly define the experimental outcomes
assessed
Show all individual data points used for analysis
External validity
Animal characteristics Eg, sex, age, strain
Housing Eg, littermates, mixed injured and uninjured
Experimental procedures Provide details of procedures for each
experimental group
Eg, drug formulation, site of injection, surgical
procedure, anaesthesia and analgesia, time of
day of testing, etc
Previous treatments Were the animals naive (if not state test/drug
history)?
Reproducibility Was the study repeated?
Clear reporting of if and how internal validity was controlled will enable experiments to be evaluated more
reliably in the context of other work in the field. External validity (examples of which came up in discussion are
listed in the lower panel) can be described in simple, clear statements in the methods and will enhance
transparency of reporting aiding faithful replication.
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assigned to a given intervention group. Concealed allocation is
different from randomization, which protects against selection
bias by balancing all confounding factors across the groups. It
should also not be confusedwith blinding, which protects against
observer bias after allocation.
Concealed allocation is a critical component of good exper-
imental design in clinical studies. Meta-analyses of human clinical
studies estimate that the efficacy of an intervention is exagger-
ated by 30% to 40% in studies with unclear or inadequately
concealed assignments.17,18 However, in preclinical studies, it is
rarely considered, and many of the participants in the PPRECISE
meeting were unaware of this principle. Applied to preclinical
studies, examples where lack of concealed allocation could
introduce bias include (1) an investigator unconsciously (or
otherwise) picking healthier subjects for the intervention group
or (2) the practice of assigning an animal to the sham surgery vs
nerve-injured groups’ midsurgery based on how well the surgery
is progressing and if the investigator easily identified the nerve. If
the allocations are done in advance and revealed only at the
moment of treatment or after the nerve is exposed, then this bias
can be mitigated. There was an overall consensus that the use or
not of concealed allocation should be reported.
4.3. Blinding (masking)
This is absolutely crucial at all levels of experimentation, from
allocation of groups, testing of responses, to final analysis of data.
However, it is recognized that it is not always possible to be truly blind
to certain test conditions (eg, an inflamed hind paw or the adopted
position of the foot after a peripheral nerve injury), and this should be
reported in publications. Measures that reduce the impact of such
loss of blinding (eg, automation or video recording where possible or
the inclusionof adummygroup in anotherwise2-groupcomparative
study) should always be considered to reduce bias. There was
a consensus that the use or not of blinding should be reported.
4.4. Randomization
Randomization is the foundation for statistical inference. It ensures
the expectation of balance among the comparison groups with
respect to the distributions of all potentially confounding factors
regardless of whether you know about them or whether you have
measured them. It is therefore very powerful. Randomization of
treatment and testing order avoids confounds, such as time of day,
cage or litter effects, and subconscious influencing of the tester.
Randomization can be performed simply by entering all information
of animals into an Excel spreadsheet and assigning each one
a random number using the “rand()” function and then sorting them
into ascending or descending order, which results in a randomized
arrangement of treatments (see http://www.3rs-reduction.co.uk/
html/5__avoiding_bias.html). There was a consensus that the use
or not of randomization should be reported.
4.5. Eligibility criteria
Predetermined eligibility criteria are scientifically and ethically
important considerations and must be reported to aid trans-
parency and to account for each animal entered into an
experiment. The criteria should always be set before the
experiment begins, and a simple statement in the methods
can explain such inclusion criteria and any exclusion criteria. For
example, it is acceptable to exclude animals that have been
tested for baseline responses before entering them into the
test phase if they do not respond within experimentally
predetermined norms. Or, if an animal is found to be ill after,
but not related to, treatment with a particular compound, eg,
poorly performed injection, it may and indeed should be
excluded from testing. However, it is very important to be sure
that exclusion is independent of treatment assignment to avoid
compromising the integrity provided by randomization. When
dealing with “outliers” in the outcome data, some at the meeting
said that they used “the 3–standard deviation rule”; that is
exclusion of data lying more than 3 SDs away from the group
mean. However, bias cannot be avoided when using such rules
unless there is a good understanding of why the outliers
occurred. Although some at the workshop believed that all data
should be included, there was a consensus that if data were
excluded, it must be reported.
4.6. Multiplicity
Issues of multiple statistical testing are pervasive in almost all
preclinical research. These typically manifest as inclusion of
multiple comparison groups, multiple outcome variables, multiple
time points at which outcomes are measured, multiple methods
for statistical analysis (eg, including and excluding “outliers” or
different methods for dealing with missing data), multiple
secondary analyses (eg, subgroup analyses), and interim
analyses of accumulating data. The implications of multiple
statistical testing are well known: if each of a collection of
statistical tests is performed using a significance level of, say, 5%,
the probability that at least one of the results is statistically
significant when the null hypothesis is actually true is greater than
5%, sometimes substantially greater. There is an extensive
literature on the problem of multiplicity and ways to address it,
although the subject is somewhat contentious as there are
several perspectives on how to approach the problem.17,18
The multiplicity issue is arguably less critical in exploratory
research, in which the researcher may be willing to accept
a higher probability of a false-positive result (ie, type I error)
knowing that it will have to be confirmed in subsequent research
(Figure 1), but if the experimental data are published before
replication is confirmed, this is a clear problem (Section 3.1,
“publication bias”). For confirmatory studies, however, research-
ers must acknowledge the problem of multiplicity and, ideally,
address it at the design stage. One way to do this is to provide
clear prioritization of comparisons, outcomes, analyses, and, so
forth, as one normally does in confirmatory clinical trials in human
subjects. Such prioritization should be clearly documented in
advance of the experiment and fully disclosed at the stage of
publication to ensure proper interpretation of the study results.
Another approach is to use appropriate statistical methods to
adjust for multiple testing. Overall, transparent reporting of all
statistical testing that was performed is recommended to allow
readers judge whether the multiplicity issues have been
addressed appropriately.
5. Discussion
The reporting of experimental methods and data in the field of
pain research must become more transparent, and greater
attention needs to be paid to internal validity (Table 1) to improve
the rigor of experimental design, which will increase the
interpretability of studies and enable high-quality meta-
analyses. We believe that these improvements will have a major
influence in ensuring the future success of pain research. Without
doubt, some of the topics discussed at the meeting produced far
more debate than others and of course this reflected the level to
April 2016·Volume 157·Number 4 www.painjournalonline.com 907
which there was agreement on how important that issue was
perceived to be to the impact on bias or transparency of
reporting.
In particular, this meeting identified major disagreements
among experts in the field with respect to the need for a priori
power calculations (section 4.1) to define sample sizes. One of
the major sticking points was how does one determine
a meaningful effect size for something entirely novel. One way
to view this would be to only consider large effect sizes, however
although this would undoubtedly reduce the number of pub-
lications, not considering small effect sizes may be an over-
simplification of the subject.
While acknowledging the unique status of pure discovery
(“hypothesis-generating”) biology, it is fair to suggest that the vast
majority of the literature does not belong to that category of
research because many studies build on those initial break-
through discoveries. However, if a study is usingmethods that are
really so original that a sample size calculation cannot be
performed, then the results should be acknowledged as
“exploratory observations” rather than “findings.” Notwithstand-
ing the issue of purely novel discovery biology, even if a completely
novel pain mechanism is being evaluated, it is often the case that
a well-established model and outcome measure are used for the
in vivo experiments. In that case, it is possible to determine
sample size by reference to effect sizes that have been seen to be
reasonable in previous reports using the same model and
outcome measure. Finally, if a trio of novel mechanism, novel
model, and novel outcome measure is used in concert, then
a suggested solution would be to have a comparative arm in the
study where animals were treated with a known standard, for
example, gabapentin (neuropathic pain), morphine (nociceptive
pain), or ibuprofen (inflammatory pain) in a knownmodel and with
a known outcome measure. This would enable the author to
compare the effect size in the novel scenario with that using
a “standard” approach potentially highlighting the value of the
new approach.
It will take more time, effort, and personnel to produce
experimental studies with high-quality design and execution but
lower-quality studies, while undoubtedly easier to perform,
produce output that is of less use, filling the field with “information
noise.” It can therefore be argued that lower-quality studies
compromise the efficiency and timeliness with which the field as
a whole moves forward. Journal editors, reviewers, and grant
funders should encourage/require greater transparency of
reporting, and many are beginning to do so. Universities have
a duty to teach students the important principles of experimental
design, sound data analysis, and transparent reporting from the
start of their scientific education so that regardless of whether
they continue in academic research or move to industry,
publishing or funding bodies, they will adopt sound principals
and be more critical of the published literature. Ultimately, this will
lead to the issues discussed herein being greatly reduced.
These recommendations are relatively straightforward and
overall benefits should be evident but will need to be assessed in
an ongoing way (eg, see Reference 2). Other issues such as
confirmation of experimental findings across independent groups
and the publication of “negative” (and “neutral”) data will require
a greater commitment by all stakeholders, but here again funders
and journalsmust take the lead. Publication decisions should give
greater weight to the rigor of the experimental design and
conduct and less to the apparent novelty or “positive” nature of
experimental findings. We believe that to achieve the goal of
finding effective new treatments for patients suffering from pain,
we need to confront and deal with these challenging issues.
Conducting high-quality science that is fully reported does not
preclude novelty and innovation in preclinical pain research;
indeed, we would argue that it will facilitate it.
Since formulating our manuscript, we note that the National
Institute of Neurological Disorders and Stroke (NINDS) has
issued guidance to researchers which are, in the main,
concordant with our suggestions (http://www.ninds.nih.gov/
funding/transparency_in_reporting_guidance.pdf).
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